Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies

March 27, 2024

https://www.globenewswire.com/news-release/2024/03/27/2853096/0/en/Aligos-Therapeutics-Presents-Positive-Clinical-Data-at-APASL-2024-from-ALG-055009-and-ALG-000184-Phase-1-Studies.html

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq:ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced three oral presentations and one poster presentation at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, being held March 27-31, 2024 in Kyoto, Japan.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.